Patient Guidelines | National Haemoglobinopathy Panel | NHP Haemoglobinopathy England | Sickle Cell Thalassaemia | Rare Inherited Anaemia UK | NHP Haemoglobinopathy England | Sickle Cell Thalassaemia | Rare Inherited Anaemia UK

Posted 21st October 2024

Posted 2 years ago

By Pfizer

Publications New Therapies Features Patient Guidelines

Pfizer Shares Patient Letter re Voxelotor (Oxybryta®) Withdrawal

Pfizer Shares Patient Advice Regarding Immediate Withdrawal of Voxelotor (Oxybryta®)

Read More
Patient Guidelines | National Haemoglobinopathy Panel | NHP Haemoglobinopathy England | Sickle Cell Thalassaemia | Rare Inherited Anaemia UK | NHP Haemoglobinopathy England | Sickle Cell Thalassaemia | Rare Inherited Anaemia UK

Posted 10th October 2024

Posted 2 years ago

By NHP Office

Publications New Therapies News & Updates Features Patient Guidelines

Voxelotor (Oxbryta®) Withdrawal - NHP Patient Letter

Following the unforeseen Pfizer withdrawal of Voxelotor (Oxbryta®) Medication for Sickle Cell Disease on 25th September 2024, the NHP provided a letter assist affected Sickle Cell Disorder patients.

Read More